Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 9/20 | 0.47 |
| ▸ | RAB9A | P51151 | 9/20 | 0.47 |
| ▸ | HPGD | P15428 | 8/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16067293 | 0.92 | ALDH1A1 (0.44) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL24340758 | 0.86 | NOTUM (0.41) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL24340743 | 0.84 | NPC1 (0.45) | ALDH1A1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL22810896 | 0.83 | ALDH1A1 (0.53) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL24450317 | 0.82 | NOTUM (0.45) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL22815021 | 0.81 | ALDH1A1 (0.42) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL26269978 | 0.80 | ALDH1A1 (0.41) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL24340791 | 0.80 | MTNR1A (0.51) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL21472918 | 0.80 | NPC1 (0.58) | KDM4EALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL31671373 | 0.79 | ALDH1A1 (0.44) | KDM4EALDH1A1NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| WO-2022056273-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | KDM4E 1852/4885ALDH1A1 1330/4885NPC1 561/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | KDM4E 2184/4885ALDH1A1 2528/4885NPC1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.